Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan)

Olsen, John O.; Pozderac, Rodney V.; Hinkle, George H.; Hill, Tim; O’Dorisio, Thomas M.; Schirmer, William J.; Ellison, E. Christopher; O’Dorisio, M. Sue

doi:10.1016/s0001-2998(95)80014-x

Cited by 99 publications

(45 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In-pentetreotide scan (Octreoscan ® , OCT) has been recognized for several years as the gold standard technique in diagnostic imaging studies for NETs and is yet the most diffuse SSA either for RGS and for SPECT. The reasons for its success, also at the present, lay in the high sensitivity and reliability of this method, recently improved thanks to the availability of hybrid SPECT/CT, for both tumor localization and staging and in follow-up [46][47][48][49].…”

Section: Neuroendocrine Tumorsmentioning

confidence: 99%

Radioguided surgery with radiolabeled somatostatin analogs: not only in GEP-NETs

2017

View full text Add to dashboard Cite

show abstract

Section: Neuroendocrine Tumorsmentioning

confidence: 99%

Radioguided surgery with radiolabeled somatostatin analogs: not only in GEP-NETs

2017

View full text Add to dashboard Cite

show abstract

“…Although these receptors are not restricted only to NETs, scintigraphy with 111 In-labelled octreotide (Octreoscan) has offered a highly sensitive tool which, when used in the relevant clinical setting, identifies and localises the tumour in patients with NETs (Krenning et al 1993, Olsen et al 1995, Kaltsas et al 2004aFig. 4).…”

Section: Octreotide Scintigraphymentioning

confidence: 99%

Paraneoplastic syndromes secondary to neuroendocrine tumours

Kaltsas

Androulakis²,

Herder³

et al. 2010

Endocrine-Related Cancer

View full text Add to dashboard Cite

Neuroendocrine tumours may be either benign or malignant tumours, and have the ability to synthesise and secrete biologically active substances characteristic of the cell of origin that can cause distinct clinical syndromes. The term 'paraneoplastic syndromes' (PNSs) is used to denote syndromes secondary to substances secreted from tumours not related to their specific organ or tissue of origin and/or production of autoantibodies against tumour cells; such syndromes are mainly associated with hormonal and neurological symptoms. Appreciation of the presence of such syndromes is important as clinical presentation, if not identified, may delay the diagnosis of the underlying neoplasia. Conversely, early recognition can allow for more rapid diagnosis, particularly as the coexistence of a neoplasm with a clinical or biochemical marker offers an additional determinant of tumour status/progression. PNSs can complicate the patient's clinical course, response to treatment, impact prognosis and even be confused as metastatic spread. Their diagnosis involves a multidisciplinary approach, and detailed endocrinological, neurological, radiological and histological studies are required. Correct diagnosis is essential as the treatment of choice will be different for each disorder, particularly in the case of malignant tumours; it is therefore important to develop appropriate means to correctly identify and localise these tumours. Clinical awareness and the incorporation into clinical practise of 111 In-octreotide scintigraphy, chromogranin A and other evolving biochemical marker measurement techniques have substantially contributed to the identification of patients harbouring such syndromes. Diseasespecific medical therapies are mandatory in order to prevent recurrence and/or further tumour growth. Owing to their rarity, central registration of these syndromes is very helpful in order to be able to provide evidence-based diagnostic and therapeutic approaches.

show abstract

“…Indium-111-pentetreotide (octreoscan) scintigraphy uses a radiolabeled SSA that can serve as a functional imaging biomarker for expression of somatostatin receptors overexpressed in the majority of GEP NETs (22), with 78% sensitivity to detect abdominal carcinoids and 67% sensitivity to detect pancreatic NETs (23), and frequently is able to detect metastatic tumors overlooked on conventional crosssectional imaging (24,25). Gallium-68-DOTA-peptide PET/CT has more recently been developed, using SSAs labelled with the positronemitting 68 Ga isotope.…”

Section: Octreotide Scintigraphymentioning

confidence: 99%

Summary of emerging personalized medicine in neuroendocrine tumors: are we on track?

Lee

O’Neil

2016

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

Neuroendocrine tumors (NETs) comprise a heterogeneous group of malignancies, with differences in prognosis and effective therapies. Traditionally, NETs have been characterized by tumor grade, site of primary tumor, functional status, and presence of underlying familial syndrome. However, increased feasibility and utilization of next-generation sequencing and other methodologies have revealed new genomic and epigenetic aberrations. In the last decade, treatment options available for metastatic well-differentiated gastroenteropancreatic (GEP) NETs have expanded, with approval of antiangiogenic and mTOR-directed targeted therapies, and our armamentarium of active therapies is likely to further increase. Cytotoxic therapies also are an important option for pancreatic NETs, and MGMT promoter methylation and protein expression may be an important biomarker for efficacy of alkylating agents. Peptide receptor radioligand therapy is an emerging treatment that uses functional imaging to personalize dosimetry to the tumor and avoid nephrotoxicity. Nevertheless, there is a critical need for further biomarkers, particularly multianalyte biomarkers, to aid in prognostication and predict efficacy of therapies.

show abstract

Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan)

Cited by 99 publications

References 17 publications

Radioguided surgery with radiolabeled somatostatin analogs: not only in GEP-NETs

Radioguided surgery with radiolabeled somatostatin analogs: not only in GEP-NETs

Paraneoplastic syndromes secondary to neuroendocrine tumours

Summary of emerging personalized medicine in neuroendocrine tumors: are we on track?

Contact Info

Product

Resources

About